Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renal Insufficiency, Chronic | 15 | 2024 | 182 | 6.530 |
Why?
|
| Renal Dialysis | 10 | 2022 | 192 | 4.160 |
Why?
|
| Kidney Failure, Chronic | 9 | 2022 | 231 | 4.020 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 5 | 2022 | 30 | 3.480 |
Why?
|
| Platelet Aggregation Inhibitors | 5 | 2023 | 180 | 2.050 |
Why?
|
| Thrombosis | 3 | 2023 | 243 | 1.680 |
Why?
|
| Blood Platelets | 2 | 2023 | 269 | 1.390 |
Why?
|
| Sertraline | 3 | 2019 | 47 | 1.290 |
Why?
|
| Depressive Disorder, Major | 3 | 2019 | 159 | 1.270 |
Why?
|
| Warfarin | 2 | 2019 | 87 | 1.250 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 475 | 1.050 |
Why?
|
| Platelet Aggregation | 3 | 2023 | 82 | 0.940 |
Why?
|
| Ticlopidine | 3 | 2023 | 57 | 0.880 |
Why?
|
| Drug Substitution | 1 | 2019 | 11 | 0.710 |
Why?
|
| Troponin T | 3 | 2017 | 12 | 0.690 |
Why?
|
| Sepsis | 1 | 2021 | 251 | 0.650 |
Why?
|
| Hemorrhage | 1 | 2019 | 208 | 0.610 |
Why?
|
| Hypocalcemia | 1 | 2017 | 13 | 0.610 |
Why?
|
| Hyperparathyroidism | 1 | 2017 | 50 | 0.590 |
Why?
|
| Humans | 26 | 2024 | 54246 | 0.580 |
Why?
|
| Parathyroidectomy | 1 | 2017 | 75 | 0.570 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 82 | 0.570 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 197 | 0.570 |
Why?
|
| Self Report | 2 | 2019 | 204 | 0.570 |
Why?
|
| Calcium | 2 | 2017 | 432 | 0.540 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 346 | 0.520 |
Why?
|
| Anticoagulants | 1 | 2018 | 270 | 0.520 |
Why?
|
| Acute Coronary Syndrome | 1 | 2016 | 91 | 0.510 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2014 | 33 | 0.500 |
Why?
|
| Primary Prevention | 1 | 2014 | 47 | 0.500 |
Why?
|
| Dialysis Solutions | 1 | 2014 | 3 | 0.500 |
Why?
|
| Hyperphosphatemia | 1 | 2014 | 2 | 0.500 |
Why?
|
| Aspirin | 1 | 2015 | 127 | 0.490 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2014 | 7 | 0.490 |
Why?
|
| Potassium, Dietary | 1 | 2014 | 2 | 0.490 |
Why?
|
| Drinking | 1 | 2014 | 78 | 0.490 |
Why?
|
| Middle Aged | 11 | 2023 | 13070 | 0.480 |
Why?
|
| Platelet Count | 2 | 2024 | 77 | 0.470 |
Why?
|
| Sodium, Dietary | 1 | 2014 | 27 | 0.470 |
Why?
|
| Administration, Oral | 3 | 2019 | 459 | 0.470 |
Why?
|
| Treatment Outcome | 7 | 2023 | 5604 | 0.450 |
Why?
|
| Acid-Base Equilibrium | 1 | 2012 | 9 | 0.440 |
Why?
|
| Adiposity | 1 | 2014 | 142 | 0.430 |
Why?
|
| Hyperkalemia | 1 | 2012 | 11 | 0.430 |
Why?
|
| Potassium | 1 | 2012 | 60 | 0.420 |
Why?
|
| Male | 14 | 2023 | 27312 | 0.410 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2016 | 338 | 0.410 |
Why?
|
| Veterans | 1 | 2018 | 629 | 0.400 |
Why?
|
| Female | 14 | 2023 | 28418 | 0.400 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 281 | 0.390 |
Why?
|
| Glomerular Filtration Rate | 4 | 2019 | 138 | 0.360 |
Why?
|
| Adenosine | 2 | 2023 | 71 | 0.350 |
Why?
|
| Depressive Disorder | 1 | 2012 | 368 | 0.350 |
Why?
|
| Risk Factors | 6 | 2019 | 3930 | 0.350 |
Why?
|
| Aged | 7 | 2022 | 10041 | 0.340 |
Why?
|
| Kidney Diseases | 1 | 2012 | 293 | 0.330 |
Why?
|
| Pyridones | 2 | 2019 | 41 | 0.330 |
Why?
|
| Kidney | 2 | 2017 | 820 | 0.320 |
Why?
|
| Pyrazoles | 2 | 2019 | 110 | 0.320 |
Why?
|
| Prognosis | 5 | 2019 | 2118 | 0.310 |
Why?
|
| Cause of Death | 3 | 2019 | 165 | 0.300 |
Why?
|
| Prospective Studies | 4 | 2019 | 2604 | 0.280 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2017 | 25 | 0.280 |
Why?
|
| Risk Assessment | 3 | 2019 | 1361 | 0.270 |
Why?
|
| Prevalence | 2 | 2019 | 1022 | 0.260 |
Why?
|
| Obesity | 1 | 2014 | 1197 | 0.260 |
Why?
|
| Peptide Fragments | 2 | 2017 | 242 | 0.260 |
Why?
|
| Disease Progression | 3 | 2019 | 913 | 0.250 |
Why?
|
| Antidepressive Agents | 2 | 2017 | 187 | 0.240 |
Why?
|
| Time Factors | 3 | 2019 | 3212 | 0.240 |
Why?
|
| Adult | 7 | 2019 | 14182 | 0.220 |
Why?
|
| Retrospective Studies | 3 | 2022 | 6432 | 0.210 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2022 | 79 | 0.200 |
Why?
|
| Coronary Artery Disease | 2 | 2017 | 329 | 0.200 |
Why?
|
| Double-Blind Method | 2 | 2019 | 742 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2015 | 1476 | 0.190 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2017 | 40 | 0.190 |
Why?
|
| E-Selectin | 1 | 2019 | 19 | 0.180 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 28 | 0.180 |
Why?
|
| Case-Control Studies | 1 | 2023 | 1228 | 0.180 |
Why?
|
| P-Selectin | 1 | 2019 | 33 | 0.180 |
Why?
|
| Arachidonic Acid | 1 | 2019 | 39 | 0.180 |
Why?
|
| Placebos | 1 | 2019 | 90 | 0.180 |
Why?
|
| Platelet Activation | 1 | 2019 | 50 | 0.180 |
Why?
|
| Peritoneal Dialysis | 1 | 2019 | 37 | 0.180 |
Why?
|
| Drug Utilization | 1 | 2019 | 74 | 0.170 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 89 | 0.170 |
Why?
|
| Fatigue | 1 | 2019 | 129 | 0.170 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 431 | 0.170 |
Why?
|
| Needs Assessment | 1 | 2019 | 154 | 0.160 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 29 | 0.160 |
Why?
|
| Antidotes | 1 | 2018 | 33 | 0.160 |
Why?
|
| Antithrombins | 1 | 2018 | 21 | 0.160 |
Why?
|
| Inflammation | 1 | 2023 | 674 | 0.160 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 2387 | 0.160 |
Why?
|
| Thiazoles | 1 | 2018 | 61 | 0.160 |
Why?
|
| Patient Selection | 1 | 2019 | 286 | 0.160 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2017 | 9 | 0.150 |
Why?
|
| Calcitriol | 1 | 2017 | 40 | 0.150 |
Why?
|
| United States | 2 | 2019 | 5200 | 0.150 |
Why?
|
| Vascular Calcification | 1 | 2017 | 26 | 0.150 |
Why?
|
| Pyridines | 1 | 2018 | 137 | 0.150 |
Why?
|
| Registries | 1 | 2019 | 553 | 0.140 |
Why?
|
| Syndrome | 1 | 2017 | 252 | 0.140 |
Why?
|
| Survival Rate | 1 | 2019 | 951 | 0.140 |
Why?
|
| Young Adult | 2 | 2019 | 4308 | 0.140 |
Why?
|
| Bone Density Conservation Agents | 1 | 2017 | 83 | 0.140 |
Why?
|
| Diphosphonates | 1 | 2017 | 96 | 0.140 |
Why?
|
| Texas | 2 | 2017 | 160 | 0.140 |
Why?
|
| Platelet Function Tests | 1 | 2015 | 20 | 0.140 |
Why?
|
| ROC Curve | 1 | 2016 | 259 | 0.140 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2014 | 6 | 0.130 |
Why?
|
| Calcinosis | 1 | 2014 | 61 | 0.120 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 426 | 0.120 |
Why?
|
| Stroke | 1 | 2019 | 524 | 0.120 |
Why?
|
| Nutrition Surveys | 1 | 2014 | 121 | 0.120 |
Why?
|
| Linear Models | 1 | 2014 | 309 | 0.110 |
Why?
|
| Triglycerides | 1 | 2014 | 195 | 0.110 |
Why?
|
| Feeding Behavior | 1 | 2014 | 199 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 259 | 0.110 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3429 | 0.110 |
Why?
|
| Hospitalization | 1 | 2016 | 705 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2014 | 310 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 596 | 0.100 |
Why?
|
| Sex Factors | 1 | 2014 | 765 | 0.100 |
Why?
|
| Blood Pressure | 1 | 2014 | 586 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2014 | 488 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2014 | 712 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2011 | 237 | 0.080 |
Why?
|
| Adolescent | 1 | 2019 | 6885 | 0.080 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 746 | 0.070 |
Why?
|
| Albuminuria | 1 | 2017 | 42 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 735 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 514 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 1084 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2017 | 411 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2014 | 13 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 1048 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 98 | 0.030 |
Why?
|
| Depression | 1 | 2017 | 594 | 0.030 |
Why?
|
| Quality of Life | 1 | 2017 | 922 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 1604 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 1213 | 0.020 |
Why?
|